Developing new methods to target cancer at the protein-membrane interface
Targeting Cancer at the Protein-Membrane Interface
This study is looking at new ways to help cancer treatments work better by targeting how proteins interact with cell membranes, which is important for cancer growth, and it could lead to new therapies that might improve outcomes for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10815876 on NIH RePORTER |
What this research studies
This research focuses on creating innovative strategies to target interactions between proteins and cell membranes, which are crucial for cancer signaling. By developing bifunctional inhibitors, the project aims to modulate these interactions to disrupt cancer cell signaling pathways. The research will explore how certain pharmacological agents can engage with membrane-integrated receptors to enhance treatment efficacy. Patients may benefit from new therapies that arise from these findings, potentially leading to more effective cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with various types of cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-malignant conditions or those who do not have a cancer diagnosis may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to groundbreaking therapies that more effectively target cancer signaling pathways.
How similar studies have performed: Other research has shown promise in targeting protein-membrane interactions for cancer treatment, indicating that this approach could be a valuable addition to existing therapies.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Morstein, Johannes — University of California, San Francisco
- Study coordinator: Morstein, Johannes
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.